Category Archives: Clinical Accelerator

Clinical Accelerator forms ClinAccel.Net

Clinical Accelerator forms ClinAccel.Net, a dedicated division focusing on expanding a network of partnering clinical research sites, and fast and efficient patient enrolment into clinical studies Douglas, February 28, 2017 – Clinical Accelerator, a clinical contract research organization with operations … Continue reading

Posted in Clinical Accelerator, Feasibility Assessment, Patient Enrolment | Leave a comment

Regulatory Approval Received for VAL401 in Phase IIB Clinical Trial in Georgia

Below, we are re-publishing with permission the press-release issued by ValiRx on August 11, 2016 London, UK., 11 August 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for … Continue reading

Posted in Clinical Accelerator | Leave a comment

Noxopharm Provides Update on Inaugural Clinical Study

Below, we are re-publishing with permission the press-release issued by Noxopharm on August 10, 2016 Noxopharm has completed putting in place the required logistics to enable it to conduct a clinical study of its lead pipeline drug candidate, NOX66, in Europe, commencing … Continue reading

Posted in Clinical Accelerator | Leave a comment

We are celebrating an important milestone: – our tenth year of operation!

We at Clinical Accelerator are happy to announce the celebration of 10 years successful provision of clinical research services to the biopharma, biotech and medtech industries. Since our inception back in 2006 as a small provider of clinical trial management … Continue reading

Posted in Clinical Accelerator | Leave a comment

Galmed Collaboration Announcement

Clinical Accelerator are very pleased to announce collaboration with Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), on conducting a phase IIB clinical trial for the treatment of patients with overweight or obesity and who are pre diabetic or type II diabetic with … Continue reading

Posted in Clinical Accelerator | Tagged | Leave a comment

Replicor to present pre-clinical and updated clinical data on REP 2139-Ca based combination therapy in chronic HBV and HBV / HDV co-infection at APASL 2016

Below, we are re-publishing with permission the press-release issued by Replicor on the 16th of February 2016 NEW YORK, February 16, 2016 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and … Continue reading

Posted in Clinical Accelerator | Leave a comment

Replicor discloses continued improvement of the antiviral response in patients with HBV / HDV co-infection receiving REP 2139-Ca based combination therapy

Below, we are re-publishing with permission the press-release issued by Replicor on the 16th of November 2015 NEW YORK, November 16, 2015 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and … Continue reading

Posted in Clinical Accelerator | Leave a comment

Replicor announces initiation of recruitment for its Phase IIb clinical trial with REP 2139-Mg or REP 2165-Mg in combination with Viread® and Pegasys® or Zadaxin® in patients with HBeAg negative chronic hepatitis B infection*

Below, we are re-publishing with permission the press-release issued by Replicor on the 4th of October 2015 New York – October 4, 2015 – Replicor announces that the recruitment of patients is underway for its second Phase II trial in Caucasian patients … Continue reading

Posted in Clinical Accelerator | Leave a comment

D-Pharm receives final report for Phase 2 clinical study of DP-b99 in acute high-risk pancreatitis patients*

Below, we are re-publishing with permission the press-release issued by D-Pharm on the 30th of July 2015 The study results imply that further trials with DP-b99 for this indication may be warranted D-Pharm Ltd (TASE:DPRM) announced today July 30th 2015, final … Continue reading

Posted in Clinical Accelerator | Leave a comment

ValiSeek and Clinical Accelerator establish a clinical research collaboration

Below, we are re-publishing with permission the press-release issued by ValiRx on the 16th of July 2015 ValiRx Plc (“ValiRx” or the “Company”)  ValiSeek Clinical Development Update Further to the announcement of 14 May 2015, ValiRx Plc (AIM: VAL) is … Continue reading

Posted in Clinical Accelerator | Leave a comment